Perphenazine picture

N o ndvertisenlciit to aid, i~rnrnote, or assist directly or indirectly ally conwmer lm9e s11; lll state tlre a i ~ ally ~ I D the , ililllil ; cr of r~ ~nil ~ a y tllnt II~ l ll s, airy or no d tor olllel- l ~ i l nist rcqoircd a t inl ception of the leas . onless t l ~ 1rcrtisc1rlcut also btilt is clearly, ronspicnoosl~.aild in cq11: 11q i z r priirt. : lnd. The following may be especially important in patient monitoring other tests may be warranted in some patients, depending on condition ; . Abnormal Movement Determinations Recommended every 2 months during therapy for institutionalized patients, using the abnormal involuntary movement scale AIMS ; , and again at 8-12 weeks after therapy has been discontinued. Blood Cell Counts and Differential in Patients with Sore Throat and Fever or Infections May be required during high dose or prolonged therapy when symptoms of infection develop. Agranulocytosis is more likely to occur between the 4th and 10th weeks of therapy. If significant cellular depression occurs, medication should be discontinued and appropriate therapy initiated. Rechallenge in recovered patients will usually cause a recurrence of agranulocytosis. Use of alternate neuroleptics, such as haloperidol or thioxanthenes is recommended. Blood Pressure Measurements Recommended periodically to detect hypotension. Careful Observation for Early Signs of Tardive Dyskinesia Recommended at periodic intervals, especially in the elderly and other patients on high or extended maintenance dosage. Since there is no known effective treatment if the syndrome should develop, the phenothiazine should be discontinued at earliest signs, usually fine worm-like movements of the tongue, to stop further development. Hepatic Function Determinations and Urine Tests for Bilirubin and Bile May be required at periodic intervals during prolonged therapy, or if jaundice or grippe-like symptoms occur, to detect liver function impairment. These side effects are more likely to occur between the 2nd and 4th weeks of therapy. Phenothiazine should be discontinued if bilirubinemia, bilirubinuria or icterus occurs. Ophthalmologic Examinations Recommended, if possible, prior to initiation of phenothiazine therapy as a baseline. Initial screening should include measurement of visual acuity with and without refraction, a color vision test to detect possible central defects, and, if feasible, a slit-lamp microscopy study of the fundus and examination of the visual fields. Tests may be required at periodic intervals usually every 6-12 months ; during high-dose or prolonged therapy, since deposition of particulate matter in the lens and cornea has occurred with some phenothiazines. Therapy should be discontinued if corneal, defective color vision, and night blindness are early symptoms of pigmentary retinopathy and may be reversible if detected and the phenothiazine discontinued in the early stages. Phenothiazine Concentrations Serum Determinations recommended when toxicity or poor response occurs, or when noncompliance is suspected. The use of phenothiazine derivatives in patients with diminished renal function should be undertaken with caution. Use with caution in patients suffering from respiratory impairment due to acute pulmonary infections, or in chronic respiratory disorders such as severe asthma or emphysema. In general, phenothiazines, including perphenazine, may produce psychic dependence. Gastritis, nausea and vomiting, dizziness, and tremulousness have been reported following abrupt cessation of highdose therapy. Reports suggest that these symptoms can be reduced by continuing concomitant antiparkinson agents for several weeks after the phenothiazine is withdrawn. The possibility of liver damage, corneal and lenticular deposits and irreversible dyskinesias should be kept in mind when patients are on long-term therapy. Because photosensitivity has been reported, undue exposure to the sun should be avoided during phenothiazine treatment. Use with caution in patient who will be exposed to extreme heat or organic phosphate insecticides. Long-term Therapy To reduce the likelihood of adverse reactions related to cumulative drug effects, patients with a history of long-term therapy with perphenazine and or other neuroleptics should be evaluated periodically, in order to determine whether the maintenance dosage could be lowered or drug therapy discontinued.

Suggesting that the rapid death observed in the previous study was due to desiccation 2 ; . Our data suggest that moist surfaces in hospitals may provide a suitable setting for vegetative C. difficile to persist for several hours. Such surfaces could include toilets and their immediate surroundings, sinks, food trays, beds, linens, moist dressings and even skin. While most work has appropriately examined environmental contamination by spores, future studies to identify environmental contamination by vegetative C. difficile are indicated Review De Wet 1965 ; : 245 first-trimester exposed pregnancies. No increase of congenital anomalies in the offspring. Case reports Cleary 1977 ; O'Connor et al 1981 ; : 2 healthy newborns exposed throughout pregnancy Donaldson and Bury 1982 ; : 1 newborn exposed monthly and throughout pregnancy to fluphenazine had cleft lip palate, imperforate anus, hypospadia, scrotum bifidus, and facies dismorphica. Merlob et al 1993 ; : 1 newborn exposed throughout pregnancy to fluphenazine and alprazolam had esophageal reflux and left hydronephrosis. A second pregnancy exposed to fluphenazine and trihexyphenidyl has resolved into a newborn with no congenital anomalies. Retrospective cohort studies with internal controls Rosa 1993 ; , Michigan MSS: 13 first trimester exposures, 1 newborn with major defects, 0.6 expected. RR 1.7 CI 95%: 0.0-9.3 ; . Prospective cohort studies with internal controls Heinonen et al 1977 ; CPP: the agent has been studied along with more phenothiazines in a total of 71 exposures 9 of which to fluphenazine ; occurred in the first 16 weeks, and 5 newborns had congenital anomalies. ARR for every type of malformation, for the entire surveyed group 1.6 CI 95%: 0.7-3.6 ; . Feto-neonatal effects: extrapyramidal reactions were noticed in exposures late in pregnancy muscular rigidity, generalized hypertonia, and tremors ; by Cleary 1977, O'Connor et al 1981, and Nath et al 1996 ; . Perphenazine N05AB03 Patented in 1956. Case Reports Wertelecki et al 1980 ; : 1 newborn exposed to toxic doses of perphenazine and amitriptyline to commit suicide on day 8 of pregnancy caused multiple defects. Cohort studies without controls Harer 1958 ; : 56 exposures in the first trimester showed no increase of congenital anomalies. Retrospective cohort studies with internal controls Rosa 1993 ; , Michigan MSS: of 140 first trimester exposures, 5 newborns had major defects, 6 expected. RR 0.8 CI 95%: 0.3-1.9 ; . Prospective cohort studies with internal controls Heinonen et al 1977 ; , CPP: of 63 exposures in the early 16 weeks of pregnancy, 2 newborns had congenital anomalies. ARR 0.7 CI 95%: 0.2-2.7 ; . Trifluperazine N05AB06 Patented in 1956. Case Reports Corner 1962 ; : a couple of twins exposed in the first six months of pregnancy, both showing hypo-agenesis of the 4 limbs. Canadian Department of National Health and Welfare 1962 ; : 8 exposed newborns had hypo-agenesis of limbs. Hall 1963 ; : 1 newborn exposed to trifluperazine for 2-3 days around day 25 of gestation showed hypo-agenesis of limbs.

Perphenazine info